Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies

Ajay Prakash, Catherine S. Diefenbach

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The activity of T-cell-mediated immunotherapies in B-cell lymphoma has been limited to date. The novel bispecific antibody CD20-TCB has a 2:1 antibody design to maximize T-cell engagement and demonstrates activity in preclinical models. This may represent a novel therapeutic approach for patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

Original languageEnglish (US)
Pages (from-to)46314632
Number of pages1
JournalClinical Cancer Research
Volume24
Issue number19
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2018 American Association for Cancer Research.

Fingerprint

Dive into the research topics of 'Immunity war: A novel therapy for lymphoma using T-cell bispecific antibodies'. Together they form a unique fingerprint.

Cite this